Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors

NCT04272034 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04272034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Terminated
Start date
March 26, 2021
Completion date
August 16, 2024
Enrollment
105 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, anal carcinoma, basal cell carcinoma (unresectable or metastatic), cervical cancer, clear cell ovarian or endometrial carcinoma, cutaneous squamous cell carcinoma, cyclin-dependent kinase 12 mutated tumors, dna polymerase epsilon mutated tumors (p286r and v411l), esophageal squamous cell carcinoma, merkel cell carcinoma, mesothelioma, msi-h/dmmr tumors, nasopharyngeal carcinoma, pd-l1 amplified tumor (9p24.1), sarcomatoid renal cell carcinoma, small-cell lung cancer, squamous cell penile carcinoma, urothelial carcinoma, hcc